123 related articles for article (PubMed ID: 350462)
1. Detection of lymphotoxins in vivo. I. Specific identification of short-lived LT activity in the plasma of various human patients employing rabbit anti-human LT sera in vitro.
Granger GA; Shimizu I; Harris L; Andreson J; Horn P
Clin Immunol Immunopathol; 1978 May; 10(1):104-15. PubMed ID: 350462
[No Abstract] [Full Text] [Related]
2. Mechanisms of lymphocyte-mediated cytotoxicity. I. The effects of anti-human lymphotoxin antisera on the cytolysis of allogeneic B cell lines by MLC-sensitized human lymphocytes in vitro.
Ware CF; Granger GA
J Immunol; 1981 May; 126(5):1919-26. PubMed ID: 6452481
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of alpha-lymphotoxin in human rejected renal allografts.
Moy J; Rosenau W
Clin Immunol Immunopathol; 1981 Jul; 20(1):49-56. PubMed ID: 7021029
[No Abstract] [Full Text] [Related]
4. The human LT system. IV. Studies on the large MW LT complex class: association of these molecules with specific antigen binding receptor(s) in vitro.
Hiserodt JC; Yamamoto RS; Granger GA
Cell Immunol; 1978 Dec; 41(2):380-96. PubMed ID: 83202
[No Abstract] [Full Text] [Related]
5. Mechanisms of lymphocyte-mediated cytotoxicity. II. biochemical and serologic identification of a precursor lymphotoxin form (pre-LT) produced by MLC-sensitized human T lymphocytes in vitro.
Ware CF; Harris PC; Granger GA
J Immunol; 1981 May; 126(5):1927-33. PubMed ID: 6163823
[No Abstract] [Full Text] [Related]
6. Identification of membrane-associated lymphotoxin (LT) on mitogen-activated human lymphocytes using heterologous anti-LT antisera in vitro.
Hiserodt JC; Ware CF; Harris PC; Granger GA
Cell Immunol; 1977 Dec; 34(2):326-39. PubMed ID: 303942
[No Abstract] [Full Text] [Related]
7. A physicochemical and immunologic comparison of the cell growth inhibitory activity of human lymphotoxins and interferons in vitro.
Ware CF; Granger GA
J Immunol; 1979 May; 122(5):1763-70. PubMed ID: 312850
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of lymphocyte-mediated cytotoxicity. III. Characterization of the mechanism of inhibition of the human alloimmune lymphocyte-mediated cytotoxic reaction by polyspecific anti-lymphotoxin sera in vitro.
Ware CF; Granger GA
J Immunol; 1981 May; 126(5):1934-40. PubMed ID: 6971314
[No Abstract] [Full Text] [Related]
9. Effect of anti-lymphotoxin on cell-mediated cytotoxicity. Evidence for two pathways, one involving lymphotoxin and the other requiring intimate contact between the plasma membranes of killer and target cells.
Gately MK; Mayer MM; Henney CS
Cell Immunol; 1976 Nov; 27(1):82-93. PubMed ID: 186197
[No Abstract] [Full Text] [Related]
10. Role of lymphotoxin in antibody-dependent cell-mediated cytotoxicity (ADCC).
Kondo LL; Rosenau W; Wara DW
J Immunol; 1981 Mar; 126(3):1131-3. PubMed ID: 6970216
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis.
Yoshimatsu H; Okazaki F; Ieiri I; To H
Chronobiol Int; 2014 May; 31(4):564-71. PubMed ID: 24517140
[TBL] [Abstract][Full Text] [Related]
12. The human LT serum. X. The initial form released by T-enriched lymphocytes is 150,000 m.w., associated with small nonlytic components, and can dissociate into the smaller alpha, beta, and gamma m.w. classes.
Harris PC; Yamamoto RS; Crane J; Granger GA
J Immunol; 1981 Jun; 126(6):2165-70. PubMed ID: 6164723
[TBL] [Abstract][Full Text] [Related]
13. In vitro protective and enhancing effects of interferons from several species on human lymphotoxin-induced target cell killing.
Williams TW; Bellanti JA
Cell Immunol; 1984 Feb; 83(2):255-61. PubMed ID: 6198099
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of lymphotoxin analysis].
Kasakura S
Nihon Rinsho; 1990 Feb; 48 Suppl():826-9. PubMed ID: 2355618
[No Abstract] [Full Text] [Related]
15. The role of lymphotoxin signaling in the development of autoimmune pancreatitis and associated secondary extra-pancreatic pathologies.
Seleznik GM; Zoller J; O'Connor T; Graf R; Heikenwalder M
Cytokine Growth Factor Rev; 2014 Apr; 25(2):125-37. PubMed ID: 24508087
[TBL] [Abstract][Full Text] [Related]
16. [Cytotoxic cytokines in multiple sclerosis].
Głabiński A
Neurol Neurochir Pol; 1993; 27(6):869-75. PubMed ID: 8164782
[TBL] [Abstract][Full Text] [Related]
17. Studies of human lymphocyte interactions with emphasis on soluble suppressor activity.
Williams RC; Korsmeyer SJ
Clin Immunol Immunopathol; 1978 Mar; 9(3):335-49. PubMed ID: 146582
[No Abstract] [Full Text] [Related]
18. [In vitro study of the cytotoxicity of sera from patients with multiple sclerosis and other neurological diseases to cultured rat oligodendrocytes].
Hirayama M; Kawai K; Iida M; Sobue I
Rinsho Shinkeigaku; 1986 Aug; 26(8):835-40. PubMed ID: 3802676
[No Abstract] [Full Text] [Related]
19. Antibodies against human lymphokines: I. Methods for induction of antibodies capable of neutralizing stable (alpha) and unstable (beta) lymphotoxins released in vitro by activated human lymphocytes.
Lewis JE; Carmack CE; Yamamoto R; Granger GA
J Immunol Methods; 1977; 14(2):163-76. PubMed ID: 557069
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity of lymphocytes. VI. Heterogeneity of cytotoxins in supernatants of mitogen-activated lymphocytes.
Walker SM; Lee SC; Lucas ZJ
J Immunol; 1976 Mar; 116(3):807-15. PubMed ID: 1082895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
